LOGIN  |  REGISTER
Astria Therapeutics

Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2024 Earnings Release

February 06, 2025 | Last Trade: US$23.84 4.85 -16.90

FRANKLIN, Tenn. / Feb 06, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2024 results on Thursday, February 27, 2025, after the close of the market. Acadia will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on Friday, February 28, 2025. A live broadcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.

About Acadia Healthcare

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2024, Acadia operated a network of 260 behavioral healthcare facilities with approximately 11,300 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page